Bristol-Myers Squibb Company (NYSE:BMY) currently has a “Buy” signals on Composite indicators by TrendSpotter. While the Short-Term Technical Indicators for the stock on 7-Day Average Directional Indicator shows “Sell” signal. 10 – 8 Day Moving Average Hilo Channel shows “Hold” signal. While 20-Day Moving Average VS Current Price shows “Sell” Signal.
Bristol-Myers Squibb Company (NYSE:BMY) lost -1.14 Percent and closed its previous trading session at $66.68. The stock traded with the average Volume of 7.53 Million at the end of last session.
Bristol-Myers Squibb Company (NYSE:BMY) has the Market Capitalization of 109.09 Billion. The Stock has its 52-week High of $70.05 and 52-Week Low of $51.56 and it touched its 52-week high on 02/16/18 and 52-Week Low on 06/07/17.
The company reported its last earnings Actual EPS of $0.68/share. While, the analyst predicted that the company could provide an EPS of $0.67/share. Hence the difference between Predicted EPS and Actual EPS reported is $0.01/share which shows an Earnings Surprise of 1.5 Percent.
Sell side analysts plays vital role in buying and selling a stock where 2 analysts rated Bristol-Myers Squibb Company (NYSE:BMY) as Buy, 0 analysts given Outperform signal, 4 reported Hold, and 0 analysts rated the stock as Sell.
The stock’s current distance from 20-Day Simple Moving Average (SMA20) is 0.04% where SMA50 and SMA200 are 4.03% and 10.01% respectively.
The company shows its Return on Assets (ROA) value of 3%. The Return on Equity (ROE) value stands at 7.2%. While it’s Return on Investment (ROI) value is 20.2%.
Bristol-Myers Squibb Company (NYSE:BMY) currently has a Weekly Volatility of 2.05% percent while its Monthly Volatility is at 2.36% percent. While talking about Performance of the Stock, Bristol-Myers Squibb Company currently has a Weekly performance of 1.85%, monthly performance percentage is 6.35 percent, Quarterly performance is 6.82 percent, 6 months performance shows a percent value of 6.31% and Yearly Performance is 17.13 percent.
Bristol-Myers Squibb is a differentiated company, led by their unique BioPharma strategy that leverages the reach and resources of a major pharma company paired with the entrepreneurial spirit and agility of a biotech firm. They work every day to deliver innovative medicines for patients with serious and life-threatening diseases. Their employees around the world work together for patients – it drives everything they do. They are focused on helping millions of patients around the world in disease areas such as oncology, cardiovascular, immunoscience and fibrosis. Through their R&D organization, they have built a sustainable pipeline of potential therapies, and actively partner to access external innovation to broaden and accelerate their work.